SC
TEVA icon

Solstein Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Solstein Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.22M Sell
95,075
-2,500
-3% -$83.3K 1.1% 23
2026
Q1 		$2.94M Buy
97,575
+2,500
+3% +$80.4K 1.21% 21
2025
Q4 		$2.97M Hold
95,075
– – 1.19% 19
2025
Q3 		$1.92M Buy
95,075
+38,475
+68% +$676K 0.44% 29
2025
Q2 		$949K Buy
+56,600
New +$913K 0.49% 46

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Solstein Capital's TEVA Position: Q2 2026 in Review

Solstein Capital reduced its Teva Pharmaceuticals (TEVA) stake by 2.6% in Q2 2026, selling an estimated $83.3K and leaving 95,075 shares worth $3.22M. The position accounts for 1.1% of the portfolio, ranked #23.

Solstein Capital first reported a position in TEVA in Q2 2025 and has held it in 5 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Solstein Capital held 95,075 shares of Teva Pharmaceuticals worth $3.22M as of Q2 2026.
  • Solstein Capital sold 2,500 Teva Pharmaceuticals shares in Q2 2026, an estimated $83.3K.
  • Teva Pharmaceuticals made up 1.1% of Solstein Capital's portfolio in Q2 2026, its #23 holding.
  • Solstein Capital first reported a position in Teva Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Solstein Capital's 13F filing for Q2 2026, filed 13 Aug 2026.